Mapping Exposure-Induced Immune Effects: Connecting the Exposome and the Immunome
About
Immune-mediated, non-communicable diseases, such as autoimmune diseases, allergic diseases and asthma, are chronic disorders in which the immune system plays a pivotal role. The World Health Organisation (WHO) has highlighted the seriousness of autoimmunity and its association with exposure to the environment.
EXIMIOUS aims to deliver a new way of assessing the human exposome, i.e. the exposures to environmental factors that one experiences throughout life, and shed light on its association to immune-mediated diseases.
Partners
EXIMIOUS is part of the European Human Exposome Network and brings together 15 partner organisations from 7 European countries.
Latest Tweets
Latest news
Registration is open for the 5th EXIMIOUS Symposium
Join us online on 28 September 2023 from 16:00 – 18:00 CEST for the EXIMIOUS Symposium “Risk assessment of mixed exposures: particles, carcinogens, and EU policies”.
Partner in the spotlight: REGIONH
Bispebjerg Hospital at Region Hovedstaden (REGIONH) in Denmark is our next partner in the spotlight. It is a large community hospital with many different specialties, complex patient cases and a diverse patient group.
Third EXIMIOUS Newsletter out now – birds and bronchi inflammation
Researchers at Vall d’Hebron Research Institute tell us about their cohort studies related to park surveillance and the health risks associated with it.
Project facts
EXIMIOUS is a 5 year Research and Innovation Action funded by the European Union’s Horizon 2020 programme.
- Concept: introduce a new approach to mapping exposure-induced immune effects by combining exposomics and immunomics in a unique toolbox.
- Budget: 10.8 million Euro
- Duration: 01.01.2020 - 31.12.2024
FAQ
Don’t know what the exposome is?
Want to know more about exposure-related immune diseases?
Curious to know more about what to expect from this project?
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874707.
